Clinical Trials Search
A Phase 1 Study of SGN-CD48A in Patients with Relapsed or Refractory Multiple Myeloma
This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.
OBJECTIVES Primary Objective: Evaluate the safety and tolerability of SGN-CD48A in patients with RRMM. Identify the maximum tolerated dose (MTD) of SGN-CD48A in patients with RRMM. Secondary Objectives: Identify a recommended single-agent dose and schedule of SGN-CD48A. Assess PK of SGN-CD48A. Assess immunogenicity of SGN-CD48A. Assess antitumor activity of SGN-CD48A. Additional Objectives: Assess incidence and level of CD48 expression in RRMM and relationship to clinical response to SGN-CD48A. Assess biomarkers in relation to response, toxicity, and resistance to SGN-CD48A.